1512-73-8

Usage

Benzimidazole derivative

It is a chemical compound derived from benzimidazole, which is a heterocyclic aromatic organic compound.

Fluorophenyl group

The compound contains a 4-fluorophenyl group, which is a phenyl group (a six-carbon ring with a hydrogen atom replaced by a fluorine atom) attached to the structure.

Ethenyl group

The compound also features an ethenyl group (a carbon-carbon double bond) in its structure.

Potential applications

1H-Benzimidazole, 2-[2-(4-fluorophenyl)ethenyl]has potential uses in organic synthesis and pharmaceutical research.

Unique chemical structure

The compound's chemical structure and properties make it valuable for further exploration in drug discovery and development.

Ongoing research

Scientists are actively researching the potential therapeutic applications and biological activities of 1H-Benzimidazole, 2-[2-(4-fluorophenyl)ethenyl]- to determine its potential benefits for various medical conditions.

Upstream product

• 51791-26-5 3-(4-fluoro-phenyl)-propenal 
• 95-54-5 1,2-diamino-benzene 
• 459-32-5 4-fluorocinnamic acid 

Relevant academic research and scientific papers

Application of sulfonic acid fabricated cobalt ferrite nanoparticles as effective magnetic nanocatalyst for green and facile synthesis of benzimidazoles

This work represents the design and synthesis of efficient sulfonated cobalt ferrite solid acid catalyst. The synthesized solid acid green catalyst was characterized using various techniques viz. FT-IR, powder XRD, SEM, TEM and VSM. The obtained catalyst was used to synthesize biologically significant 2-substituted benzimidazole derivatives by condensation between o-phenylenediamine with various aromatic, aliphatic and heterocyclic aldehydes. High yield (up to 98 %), short reaction time (10?25 min), mild reaction condition, wide functional group tolerance, easy work-up procedure and excellent values of green chemistry metrices such as lower E factor (0.126), high RME value (88.83 %), carbon efficiency (100 %) and high atom economy (AE) value (90.65 %), are some salient features of the present catalytic system. Moreover, the catalyst recovery by simply using an external magnet and catalyst reusability up to 7 times without any significant loss in catalytic efficiency are some additional remarkable features of the current protocol.

DUAL ACTING FKBP12 AND FKBP52 INHIBITORS

Provided are novel compounds of Formulas (I) and (II), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful as dual FKBP12/FKABP inhibitors. Also provided are pharmaceutical compositions comprising the novel compounds of Formulas (I) and (II) and their use in treating Parkinson's disease.